AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20705558
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy plus zoledronic acid
Trial: 18502360
Drug: 0.0 mg
RxNorm normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 mg intrathecal morphine (Control)
Trial: 10195531
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg intrathecal morphine
Trial: 18502360
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg intrathecal morphine
Trial: 18502360
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg intrathecal morphine
Trial: 18502360
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.1 to 0.4 mg)
Trial: 21824444
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg HCA
Trial: 11443511
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg HCA and 3 g MCT
Trial: 11443511
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (PLA, HCA, HCA+MCT)
Trial: 9778328
Drug: GnRHa +
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRHa + estrogen/progestogen add-back therapy
Trial: 7820145
Drug: rHuEPO by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO by subcutaneous route, initial doses of 20U/kg/dialysis, mean correction dose of 65U/kg/dialysis, maintenance dose of 51U/kg/dialysis
Trial: 29949492
Drug: Inhaled glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticoid plus LABA (combination therapy)
Trial: 29949492
Drug: Inhaled glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticoid alone (control)
Trial: 25282874
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (MLD and control)
Trial: 22819803
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg taurine
Trial: 22819803
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg caffeine + 50 g glucose
Trial: 22819803
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg taurine + 50 g glucose
Trial: 17493196
Drug: ALN 70
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN 70 mg once a week plus calcitriol (1,25D3) 0.5 microg daily
Trial: 17493196
Drug: ALN 70
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN 70 mg once a week alone
Trial: 9609267
Drug: Oestradiol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol (2 mg daily) for 20 to 24 weeks
Trial: 7639104
Drug: Transcutaneous 17‐beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous 17‐beta‐estradiol (50 micrograms daily)
Trial: 7639104
Drug: Cyclical intravenous
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical intravenous clodronate (200 mg/month iv infusion)
Trial: 2560289
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (duration: 6 months)
Trial: 2560289
Drug: Normotensive controls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normotensive controls (no treatment)
Trial: 791563
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) at doses of 0, 150, or 500 mug/kg
Trial: 791563
Drug: Secobarbital (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secobarbital (150 mg/70 kg)
Trial: 791563
Drug: Secobarbital (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secobarbital (150 mg/70 kg) with CBD pretreatment
Trial: 23438937
Drug: Mirtazapine (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (45 mg daily)
Trial: 20638340
Drug: Atosiban (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (37.5 mg intravenous administration before embryo transfer)
Trial: 11926622
Drug: Daily PEFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily PEFR monitoring
Trial: 455950
Drug: Nonscheduled therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonscheduled therapy
Trial: 29044000
Drug: Shenqi Fuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi Fuzheng Injection combined with Cefoxitin Sodium
Trial: 23798006
Drug: Androgen suppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen suppression therapy (AST) for 6 months
Trial: 22772617
Drug: Nano-emulsion gel
RxNorm normalized name: propofol lipid emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-emulsion gel formulation of adapalene 0.1% and clindamycin 1%
Trial: 22772617
Drug: Conventional gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional gel formulation of adapalene 0.1% and clindamycin 1%
Trial: 19740402
Drug: BX471 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BX471 at therapeutic doses
Trial: 15372178
Drug: Biken two-component
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biken two-component (23.4 mg PT; 23.4 mg FHA) Pa vaccine (0.5 ml)
Trial: 3986084
Drug: Amitriptyline hydrochloride
RxNorm normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline hydrochloride (50 mg or 100 mg)
Trial: 3986084
Drug: Binodaline hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binodaline hydrochloride (50 mg or 100 mg)
Trial: 30803706
Drug: Spironolactone (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (maximum dose, 50mg/d) for 24 weeks
Trial: 25140597
Drug: Supplement with
RxNorm normalized name: NESTABS DHA Prenatal Multi-vitamin/Mineral Supplement with DHA/EPA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement with ω6:ω3 ratio of 8:1 and arginine
Trial: 25140597
Drug: Supplement with
RxNorm normalized name: NESTABS DHA Prenatal Multi-vitamin/Mineral Supplement with DHA/EPA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement with high ω9:ω6 ratio of 3.2:1 and low ω6:ω3 ratio of 1.4:1 and arginine
Trial: 19306038
Drug: Citalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (10 mg/day)
Trial: 17724802
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg/d
Trial: 17724802
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg/d
Trial: 18035206
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg/d
Trial: 11740701
Drug: Clarithromycin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (15 mg/kg/day in 2 divided doses for 7 days)
Trial: 11740701
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg/day in 1 dose for 3 days)
Trial: 19259717
Drug: ANN-guided CPAP
RxNorm normalized name: trastuzumab-anns
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ANN-guided CPAP titration
Trial: 22253054
Drug: Conventional CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional CPAP titration
Trial: 15229100
Drug: Fluticasone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (500 mcg twice a day)
Trial: 15229100
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (30 mg/day)
Trial: 15229100
Drug: Fluticasone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (500 mcg twice a day for an additional 8 weeks)
Trial: 11395591
Drug: Diltiazem (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (25 mg bolus followed by 20 mg/hr continuous infusion for 24 hrs)
Trial: 11395591
Drug: Amiodarone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (300 mg bolus)
Trial: 11395591
Drug: Amiodarone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (300 mg bolus followed by 45 mg/hr for 24 hrs)
Trial: 9244941
Drug: Propofol (0.8‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.8‐1 mg/kg for induction; 4‐6 mg/kg/h for maintenance)
Trial: 9244941
Drug: Etomidate (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.25 mg/kg for induction) and isoflurane (0.6‐0.8% for maintenance)
Trial: 26293443
Drug: BUP at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP at a dose of 150mg/day for 3 days, subsequently increased to 300mg/day
Trial: 26293443
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum of 4mg every 1-2 hourly for initial 6 weeks, then every 2-4 hourly for next 6 weeks
Trial: 26293443
Drug: Behavioral Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral Intervention (BI) + Nicotine Replacement Therapy (NRT)
Trial: 23834653
Drug: Sivelestat (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sivelestat (0.2 mg/kg/h continuous intravenous infusion)
Trial: 16960287
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (hemoglobin 7.0 g/dL maintained between 7.0 and 9.0 g/dL)
Trial: 16960287
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (hemoglobin 10.0 g/dL maintained between 10.0 and 12.0 g/dL)
Trial: 8106653
Drug: Paroxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (10 to 50 mg/day)
Trial: 3539709
Drug: Intravenous branched
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous branched chain amino acids in 20% dextrose (group A)
Trial: 3539709
Drug: Oral lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral lactulose (group B)
Trial: 3539709
Drug: Intravenous branched
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous branched chain amino acids (preliminary uncontrolled study)
Trial: 14587302
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose triple therapy (omeprazole, amoxicillin, clarithromycin) for 1 week
Trial: 14587302
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose triple therapy (omeprazole, amoxicillin, clarithromycin) for 1 week
Trial: 14587302
Drug: Failed eradication
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Failed eradication therapy
Trial: 7529038
Drug: Aprotinin (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (high-dose regimen)
Trial: 19651344
Drug: Analgesics taken
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics taken
Trial: 19651344
Drug: No analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No analgesics taken
Trial: 17804348
Drug: Peer support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer support intervention for promoting antiretroviral therapy adherence
Trial: 14987268
Drug: 6 treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 treatments of psoralen‐UVA (PUVA) therapy
Trial: 14987268
Drug: 12 treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 treatments of psoralen‐UVA (PUVA) therapy
Trial: 9551739
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules plus canola oil and margarine (omega‐3 group)
Trial: 9551739
Drug: Safflower oil
RxNorm normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil capsules plus sunflower oil and margarine (omega‐6 group)
Trial: 7998418
Drug: TGP-943 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGP-943 vaccine
Trial: 3045202
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1 g/day) for 8 weeks
Trial: 3045202
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1 g/day) for 8 weeks followed by 1,25-(OH)2 vitamin D3 (0.5 micrograms/day) for 2 weeks
Trial: 25817323
Drug: Therapist-supervised therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-supervised therapy provided by a certified hand therapist (CHT)
Trial: 21228246
Drug: Basal-bolus insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal-bolus insulin regimen (glargine once daily and glulisine before meals)
Trial: 21228246
Drug: Sliding scale
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sliding scale regular insulin (SSI) four times daily
Trial: 23435159
Drug: Sliding scale
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sliding scale regular insulin (SSI)
Trial: 18820311
Drug: Blind intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind intra-articular injections (IAIs) in peripheral joints
Trial: 16801461
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy (CRT) in patients with new-onset AF
Trial: 11035135
Drug: SR 49059
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 49059 (300 mg once daily)
Trial: 9385122
Drug: Raloxifene (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (all doses)
Trial: 1539846
Drug: PCA supplemented
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA supplemented with a nighttime infusion of morphine 1.0 mg.h-1
Trial: 30895697
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg once daily in addition to standard care
Trial: 27325392
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Treatment (CBT) + Contingency Management (CM)
Trial: 27325392
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Treatment (CBT) alone
Trial: 25035081
Drug: Fludrocortisone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone (0.4 mg)
Trial: 19527368
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for osteolymphoma (chemotherapy and radiotherapy)
Trial: 16430566
Drug: Target controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target controlled propofol 3 microg.ml(‐1) infusion
Trial: 9377859
Drug: Propranolol at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol at a dose of 240 mg/day for 30 days
Trial: 1543450
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% indomethacin aqueous suspension
Trial: 23419093
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% sodium chloride solution)
Trial: 8646143
Drug: Active cream
RxNorm normalized name: NIACINAMIDE 2 g in 100 mL / ADENOSINE 0.04 g in 100 mL TOPICAL CREAM [INCELLDERM ACTIVE CREAMEX]
DrugBank: Octisalate (DB11062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active cream
Trial: 27433837
Drug: D-002 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-002 (50 mg/d)
Trial: 27433837
Drug: D-003 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-003 (10 mg/d)
Trial: 27433837
Drug: D-002/D-003 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-002/D-003 (50 mg/d of D-002 plus 10 mg/d of D-003)
Trial: 22998742
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of buspirone 15 mg and melatonin-SR 3 mg
Trial: 22998742
Drug: Buspirone 15
RxNorm normalized name: busPIRone 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 15 mg monotherapy
Trial: 20648928
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg iron as FCM given as an i.v. bolus injection
Trial: 20648928
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg iron as FCM given as an i.v. infusion over 15 min
Trial: 20648928
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg iron as FCM given as an i.v. infusion over 15 min
Trial: 20648928
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg iron as FCM given as an i.v. infusion over 15 min
Trial: 15819586
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus clopidogrel for 12 months after PCI with DES
Trial: 15819586
Drug: Clopidogrel for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel for 4 weeks plus aspirin after PCI with DES
Trial: 15819586
Drug: Combined antithrombotic
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antithrombotic therapy with aspirin and clopidogrel
Trial: 9005786
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of ofloxacin 400 mg once a day (group I)
Trial: 9005786
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of ofloxacin 200 mg twice a day for 2 to 4 days followed by oral use of 400 mg once a day for 6 to 8 days (group II)
Trial: 1930700
Drug: Herbal ingredients
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal ingredients in toothpaste and oral rinse
Trial: 773413
Drug: Placebo preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo preparations
Trial: 7074749
Drug: Flecainide acetate
RxNorm normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flecainide acetate (average daily dose 436 mg)
Trial: 7074749
Drug: Flecainide therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide therapy
Trial: 7074749
Drug: Flecainide therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide therapy after 1 week
Trial: 7074749
Drug: Flecainide therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide therapy after 2 weeks
Trial: 7074749
Drug: Flecainide concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide concentrations of 200‐800 ng/ml
Trial: 31291207
Drug: cCBT program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cCBT program 'Good Days Ahead' with weekly guidance and support
Trial: 12653894
Drug: Phenobarbital (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (150 mg) for 7 days
Trial: 12653894
Drug: Phenobarbital (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (150 mg) for 7 days in subgroup IB (n = 22)
Trial: 10591823
Drug: Ondansetron orally
RxNorm normalized name: Ondansetron Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron orally disintegrating tablet (ondODT) 8 mg
Trial: 10591823
Drug: Ondansetron orally
RxNorm normalized name: Ondansetron Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron orally disintegrating tablet (ondODT) 16 mg
Trial: 8877126
Drug: 15-, 45-,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-, 45-, or 135-micrograms doses of monovalent influenza A/Taiwan (H1N1) hemagglutinin (HA) vaccine
Trial: 8877126
Drug: 15-, 45-,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-, 45-, or 135-micrograms doses of subvirion (SV) vaccine